TY - JOUR
T1 - Use of Statins in Patients with Chronic Liver Disease and Cirrhosis
T2 - Current Views and Prospects
AU - Vargas, Jose Ignacio
AU - Arrese, Marco
AU - Shah, Vijay H.
AU - Arab, Juan Pablo
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
AB - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
KW - Chronic liver diseases
KW - Cirrhosis
KW - Drug-induced liver injury
KW - HMG-CoA reductase inhibitors
KW - Hepatocellular carcinoma
KW - Portal hypertension
KW - Statins
KW - Variceal bleeding
UR - http://www.scopus.com/inward/record.url?scp=85026643973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026643973&partnerID=8YFLogxK
U2 - 10.1007/s11894-017-0584-7
DO - 10.1007/s11894-017-0584-7
M3 - Review article
C2 - 28752475
AN - SCOPUS:85026643973
VL - 19
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
SN - 1522-8037
IS - 9
M1 - 43
ER -